Genus: Underlying Group Trading In-line With Expectations

Genus (GNS.L) issued a strong fiscal year 2025 trading update, projecting adjusted profit before tax (PBT) of at least £72 million, which includes a significant PRP milestone receipt. Excluding this receipt, PBT is expected to be at least £68 million, aligning with prior expectations. The company also reported strong underlying trading performance and very strong second-half cash conversion, resulting in robust free cash flow growth.

Analysis

Genus (GNS.L) issued a positive trading update for fiscal year 2025, upgrading its adjusted profit before tax (PBT) guidance to at least £72 million in actual currency. This figure is bolstered by a key PRP milestone receipt; the underlying adjusted PBT is forecast to be at least £68 million, which aligns with existing market expectations, indicating solid core business performance. Importantly, the update highlights very strong cash conversion in the second half, which has translated into strong growth in free cash flow. This combination of meeting underlying profit expectations and demonstrating robust cash generation suggests high-quality earnings and solid operational health, providing a degree of certainty for investors ahead of the full preliminary results scheduled for September 4, 2025.

Key Decisions for Investors

• Investors should view this update as a confirmation of the company's solid operational execution, supported by both in-line underlying profit and strong free cash flow generation.
• The one-off nature of the PRP milestone receipt means forward-looking models should be based on the underlying £68 million profit guidance to avoid overstating the sustainable earnings power of the business.
• It is prudent to monitor the upcoming preliminary results on September 4, 2025, for further details on cash flow sustainability and management's outlook for fiscal 2026.